Evidence map›Paper›PMID 37211818›Full record

ArticleVascular medicine (London, England)2023

Patient and limb outcomes 10 years after endovascular revascularization of the superficial femoral artery for peripheral artery disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) study.

Scott Kinlay, Piotr Sobieszczyk, Andrew C Eisenhauer, Simon Ostrowski, Thomas M Todoran

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular medicine (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Major Adverse Limb Events and Death After Successful Endovascular Revascularization: BEST-CLI Trial.Journal of the Society for Cardiovascular Angiography & Interventions · 2026
    Article
  3. Revascularization for Chronic Limb-Threatening Ischemia-Synthesizing Inconsistency.Journal of the Society for Cardiovascular Angiography & Interventions · 2025
    Article
  4. Article
  5. Long-Term Adverse Limb Events After Femoral Artery Endovascular Revascularization: The Boston FAROUT Study.Journal of the Society for Cardiovascular Angiography & Interventions · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Scott KinlayCardiovascular Division, Department of Medicine, Veterans Affairs Boston Healthcare System, West Roxbury, MA, USA.ORCID 0000-0001-7687-9136
Piotr SobieszczykCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Andrew C EisenhauerCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Simon OstrowskiUniversity of Pittsburgh, Pittsburgh, PA, USA.
Thomas M TodoranMedical University of South Carolina, Charleston, SC, USA.
Brigham and Women's Hospital · USMedical University of South Carolina · USUniversity of Pittsburgh · US

Funding

Rationalizing Duration of Dual Antiplatelet Therapy After Coronary StentingI01CX001549 · VA · VA BOSTON HEALTH CARE SYSTEM · PI KINLAY, SCOTT · 2017 to 2021
–
CSRD VA I01 CX001549
6 · The paper itself

Abstract

backgroundWe aimed to describe patient and limb outcomes in the decade after endovascular revascularization for chronic lower-extremity peripheral artery disease (PAD).

methodsWe assessed outcomes in patients having endovascular revascularization of the superficial femoral artery in two centers between 2003 and 2011 and followed for a median 9.3 (25-75%: 6.8, 11.1) years. Outcomes included death, myocardial infarction, stroke, repeat limb revascularizations, and amputations. We used competing risks analysis with clustering by patient to determine the hazard ratios (HR) and 95% CI for patients, and procedural characteristics for cause of death, cardiovascular events, and major adverse limb events (MALE).

resultsThere were 253 index limb revascularizations in 202 patients followed for a median 9.3 years. Patients had intensive medical treatment with 90% on statins and 80% on beta-blockers. During follow up there were 57 (28%) cardiovascular deaths and 62 (31%) noncardiovascular deaths. Of the 253 limbs, 227 (90%) were free of MALE over follow up and 93 (37%) had MALE or minor repeat revascularization. In multivariable models, cardiovascular death significantly associated with critical limb ischemia (HR = 3.21, 95% CI = 1.84, 5.61) and noncardiovascular death with chronic kidney disease (HR = 2.69, 95% CI = 1.68, 4.30), and smoking (HR = 2.75, 95% CI = 1.01, 7.52). MALE or minor repeat revascularization associated with critical limb ischemia (HR = 1.43, 95% CI = 0.84, 2.43), smoking (HR = 2.49, 95% CI = 1.26, 4.90), and lesion length > 200 mm (HR = 1.51, 95% CI = 0.98, 2.33).

conclusionsAmong patients with intensive medical therapy, the risk of noncardiovascular death was high and similar to cardiovascular death. Endovascular intervention can have acceptable long-term results. Future studies should evaluate strategies to reduce both cardiovascular and noncardiovascular deaths.

Indexed as

Endovascular ProceduresPeripheral Arterial DiseaseBostonChronic Limb-Threatening IschemiaFemoral ArteryHumansIschemiaLimb SalvageLower ExtremityRisk FactorsTreatment Outcomeclinical outcomesendovascularfemoral arterylimb outcomes, peripheral artery disease (PAD)

Identifiers

PMID37211818
PMCPMC10527919
OpenAlexW4377221191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.